PORTRAZZA

This brand name is authorized in Austria, Estonia, Ireland, Japan, Lithuania, Poland, Singapore, United States

Active ingredients

The drug PORTRAZZA contains one active pharmaceutical ingredient (API):

1 Necitumumab UNII 2BT4C47RUI - NECITUMUMAB

Human normal immunoglobulin contains mainly immunoglobulin G (IgG) with a broad spectrum of antibodies against infectious agents. Human normal immunoglobulin contains the IgG antibodies present in the normal population. It is usually prepared from pooled plasma from not fewer than 1000 donors. Read about Human normal immunoglobulin G

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
Portrazza Solution for injection	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FE03	Necitumumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FE EGFR (Epidermal Growth Factor Receptor) inhibitors
Discover more medicines within L01FE03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1711639
Country: JP	医薬品医療機器総合機構	Identifier(s): 4291448A1026
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1079701
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100366940
Country: SG	Health Sciences Authority	Identifier(s): 15292P
Country: US	FDA, National Drug Code	Identifier(s): 0002-7716